Literature DB >> 33199077

Incidence of community-acquired pneumonia in urban China: A national population-based study.

Yixin Sun1, Hui Li2, Zhengcun Pei1, Shengfeng Wang1, Jingnan Feng1, Lu Xu1, Pei Gao1, Bin Cao3, Siyan Zhan4.   

Abstract

BACKGROUND: Community-acquired pneumonia (CAP) is one of the major global health problems worldwide. However, the epidemiological information of CAP is limited in China. This study aimed to estimate the incidence rate of CAP and describe the epidemiologic characteristics among the Chinese population.
METHODS: We conducted a retrospective analysis of CAP incidence using the Chinese Urban Basic Medical Insurance database of 23 provinces in 2016, which covered 427.52 million urban beneficiaries of all age groups in Mainland China. CAP episodes were identified using a diagnosis-term-derived algorithm, and multiple CAP records of one single person within 90 continuous days were considered as one single episode. The incidence rates were calculated and described by sex, age, region, and season.
RESULTS: A total of 1.42 million patients were identified as having one or more CAP episodes, and finally a sum of 1.48 million CAP episodes were counted. The overall incidence of CAP was 7.13 (95% CI: 6.11-8.15) per 1000 person-years, in males 7.32 (95% CI: 6.28-8.35) and females 6.93 (95% CI: 5.92-7.94) per 1000 person-years, respectively. The incidence varied by age with a U-shaped curve peaking in children aged < 5 years old [65.80 (95% CI: 62.52-69.08)] and elderly population aged ≥ 80 years old [14.98 (95% CI: 13.63-16.34)]. The incidence varied markedly by regions. Furthermore, the rate showed a clear seasonal trend, which peaked in spring, decreased in summer and autumn, and re-ascended in winter.
CONCLUSION: This study reveals a relatively high level of CAP incidence in China. These findings provide baseline data for establishing effective prevention strategies, targeted at susceptible populations, regions, and seasons in China.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Claim database; Community-acquired pneumonia; Epidemiology; Incidence

Mesh:

Year:  2020        PMID: 33199077     DOI: 10.1016/j.vaccine.2020.11.004

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  The association between hypogammaglobulinemia severity and infection risk in rituximab-treated patients with childhood-onset idiopathic nephrotic syndrome.

Authors:  Yuta Inoki; Kentaro Nishi; Mai Sato; Masao Ogura; Koichi Kamei
Journal:  Pediatr Nephrol       Date:  2022-06-24       Impact factor: 3.714

2.  Incidence and disease burden of community-acquired pneumonia in southeastern China: data from integrated medical resources.

Authors:  Ning Jiang; Ran Li; Jing Bao; Yu Xie; Xiqian Ma; Yukun He; Yan Yu; Yusheng Chen; Hongru Li; Yali Zheng; Qing Xue; Jiangxi Wu; Yu Xu; Chuanxi Fu; Zhancheng Gao
Journal:  Hum Vaccin Immunother       Date:  2021-11-19       Impact factor: 3.452

3.  Chinese Patent Medicine Shufeng Jiedu Capsules as an Adjuvant Therapy for Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.

Authors:  Xiao-Wen Zhang; Ru-Yu Xia; Jia-Qi Gao; Jin-Jun Liu; De-Hao Xu; Xun Li; Xiao-Yang Hu; Merlin Willcox; Michael Moore; Meng-Yuan Dai; Jeanne Trill; Yu-Tong Fei; Jian-Ping Liu
Journal:  Front Pharmacol       Date:  2022-07-04       Impact factor: 5.988

4.  Building a predictive model to identify clinical indicators for COVID-19 using machine learning method.

Authors:  Xinlei Deng; Han Li; Xin Liao; Zhiqiang Qin; Fan Xu; Samantha Friedman; Gang Ma; Kun Ye; Shao Lin
Journal:  Med Biol Eng Comput       Date:  2022-04-25       Impact factor: 3.079

5.  Infectious diseases among elderly persons: Results from a population-based observational study in Shandong province, China, 2013-2017.

Authors:  Wan-Yu Du; Chao-Nan Yin; Hai-Tao Wang; Zhen-Wei Li; Wen-Jing Wang; Fu-Zhong Xue; Lin Zhao; Wu-Chun Cao
Journal:  J Glob Health       Date:  2021-12-25       Impact factor: 4.413

6.  Deep Learning-Based Available and Common Clinical-Related Feature Variables Robustly Predict Survival in Community-Acquired Pneumonia.

Authors:  Ding-Yun Feng; Yong Ren; Mi Zhou; Xiao-Ling Zou; Wen-Bin Wu; Hai-Ling Yang; Yu-Qi Zhou; Tian-Tuo Zhang
Journal:  Risk Manag Healthc Policy       Date:  2021-09-04

7.  Association of Admission Blood Glucose Level with All-Cause Mortality According to Age in Patients with Community Acquired Pneumonia.

Authors:  Yejing Shen; Xiaowen Xu; Siming Meng; Meng Qin; Hailing Li; Dejie Chu; Cuixia Zheng
Journal:  Int J Gen Med       Date:  2021-11-06

8.  The hospitalization burden of all-cause pneumonia in China: A population-based study, 2009-2017.

Authors:  Yizhen Hu; Yuting Han; Canqing Yu; Yu Guo; Pei Pei; Ling Yang; Yiping Chen; Huaidong Du; Dianjianyi Sun; Yuanjie Pang; Wenbin Niu; Sushila Burgess; Alex Hacker; Junshi Chen; Zhengming Chen; Jun Lv; Liming Li
Journal:  Lancet Reg Health West Pac       Date:  2022-04-06

9.  Economic Evaluation of Nemonoxacin, Moxifloxacin and Levofloxacin in the Treatment of Early Community-Acquired Pneumonia with Possible Pulmonary Tuberculosis.

Authors:  Mingye Zhao; Zhuoyuan Chi; Xingming Pan; Yue Yin; Wenxi Tang
Journal:  Int J Environ Res Public Health       Date:  2022-04-15       Impact factor: 4.614

10.  Heightened Willingness toward Pneumococcal Vaccination in the Elderly Population in Shenzhen, China: A Cross-Sectional Study during the COVID-19 Pandemic.

Authors:  Minyi Zhang; Hongbiao Chen; Fei Wu; Qiushuang Li; Qihui Lin; He Cao; Xiaofeng Zhou; Zihao Gu; Qing Chen
Journal:  Vaccines (Basel)       Date:  2021-03-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.